The Behavioral Effects of a Mixed Efficacy Antinociceptive Peptide, VRP26, Following Chronic Administration in Mice

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2016 Apr 28

PMID 27117141

Citations 10

Authors

Jessica P Anand

Brett T Boyer

Henry I Mosberg

Emily M Jutkiewicz

Affiliations

Soon will be listed here.

Abstract

Rationale: VRP26 displays mu opioid receptor agonist and delta opioid receptor antagonist activity in vitro, a pharmacological profile purported to produce reduced tolerance, dependence, and rewarding effects. We hypothesized that VRP26 would display reduced adverse effects after chronic administration as compared with the traditional opioid analgesic fentanyl.

Objective: The aim of this study is to explore the development of tolerance, dependence, and conditioned place preference of VRP26 as compared with the traditional opioid analgesic fentanyl.

Methods: The antinociceptive effects of VRP26 and fentanyl were assessed using the mouse warm water tail withdrawal (WWTW) assay. Measurement of antinociceptive tolerance and physical dependence occurred after 7 days of continuous administration of either fentanyl (0.3 mg/kg/day) or VRP26 (10 mg/kg/day); tolerance was measured by a shift in the antinociceptive dose response curve in the WWTW assay. Physical dependence was determined by observation of withdrawal symptoms after precipitated withdrawal. Rewarding effects were measured by the ability of VRP26 or fentanyl to produce conditioned place preference.

Results: Fentanyl produced significant tolerance and dependence, as well as significant conditioned place preference. VRP26 produced neither tolerance nor physical dependence, nor did it produce significant conditioned place preference.

Conclusions: These results suggest that chronic treatment with VRP26 may produce less tolerance or physical dependence than chronic treatment with clinically available mu opioid analgesics such as fentanyl. Additionally, VRP26 produces less rewarding effects than fentanyl. This desirable in vivo profile may be due to the mixed efficacy nature of VRP26 and could provide the framework for safer opioid analgesics.

Citing Articles

Peptide-derived ligands for the discovery of safer opioid analgesics.

Eliasof A, Liu-Chen L, Li Y Drug Discov Today. 2024; 29(5):103950.

PMID: 38514040 PMC: 11127667. DOI: 10.1016/j.drudis.2024.103950.

Claustral neurons projecting to frontal cortex restrict opioid consumption.

Terem A, Fatal Y, Peretz-Rivlin N, Turm H, Koren S, Kitsberg D Curr Biol. 2023; 33(13):2761-2773.e8.

PMID: 37379841 PMC: 10357322. DOI: 10.1016/j.cub.2023.05.065.

Differential Effects of a Novel Opioid Ligand UTA1003 on Antinociceptive Tolerance and Motor Behaviour.

Paul A, Woolley K, Rahmatullah M, Wilairatana P, Smith J, Gueven N Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890089 PMC: 9318816. DOI: 10.3390/ph15070789.

Synthesis and Pharmacology of a Novel μ-δ Opioid Receptor Heteromer-Selective Agonist Based on the Carfentanyl Template.

Faouzi A, Uprety R, Gomes I, Massaly N, Keresztes A, Le Rouzic V J Med Chem. 2020; 63(22):13618-13637.

PMID: 33170687 PMC: 7745089. DOI: 10.1021/acs.jmedchem.0c00901.

Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.

Vekariya R, Lei W, Ray A, Saini S, Zhang S, Molnar G J Med Chem. 2020; 63(14):7663-7694.

PMID: 32530286 PMC: 9521336. DOI: 10.1021/acs.jmedchem.0c00503.

References

Bender A, Griggs N, Anand J, Traynor J, Jutkiewicz E, Mosberg H . Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands. ACS Chem Neurosci. 2015; 6(8):1428-35. PMC: 4676711. DOI: 10.1021/acschemneuro.5b00100. View

Ballantyne J, LaForge S . Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007; 129(3):235-255. DOI: 10.1016/j.pain.2007.03.028. View

Hepburn M, Little P, Gingras J, Kuhn C . Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats. J Pharmacol Exp Ther. 1997; 281(3):1350-6. View

Ramabadran K . Effects of N-methylnaloxone and N-methylnaltrexone on nociception and precipitated abstinence in mice. Life Sci. 1982; 31(12-13):1253-6. DOI: 10.1016/0024-3205(82)90355-1. View

Purington L, Pogozheva I, Traynor J, Mosberg H . Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties. J Med Chem. 2009; 52(23):7724-31. PMC: 2788680. DOI: 10.1021/jm9007483. View

Aceto M, Harris L, Negus S, Banks M, Hughes L, Akgun E . MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys. Int J Med Chem. 2015; 2012:327257. PMC: 4412046. DOI: 10.1155/2012/327257. View

Mosberg H, Yeomans L, Anand J, Porter V, Sobczyk-Kojiro K, Traynor J . Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance. J Med Chem. 2014; 57(7):3148-53. PMC: 3993928. DOI: 10.1021/jm5002088. View

Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham D, Lambert D . Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth. 2009; 103(1):38-49. DOI: 10.1093/bja/aep129. View

Healy J, Bezawada P, Shim J, Jones J, Kane M, MacKerell Jr A . Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. ACS Chem Neurosci. 2013; 4(9):1256-66. PMC: 3778426. DOI: 10.1021/cn4000428. View

10.

Schiller P . Bi- or multifunctional opioid peptide drugs. Life Sci. 2009; 86(15-16):598-603. PMC: 2848892. DOI: 10.1016/j.lfs.2009.02.025. View

11.

Balboni G, Guerrini R, Salvadori S, Bianchi C, Rizzi D, Bryant S . Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem. 2002; 45(3):713-20. DOI: 10.1021/jm010449i. View

12.

Breitwieser G . G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ Res. 2004; 94(1):17-27. DOI: 10.1161/01.RES.0000110420.68526.19. View

13.

Salvadori S, Guerrini R, Balboni G, Bianchi C, Bryant S, Cooper P . Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism. J Med Chem. 1999; 42(24):5010-9. DOI: 10.1021/jm990165m. View

14.

Schiller P, Fundytus M, Merovitz L, Weltrowska G, Nguyen T, Lemieux C . The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem. 1999; 42(18):3520-6. DOI: 10.1021/jm980724+. View

15.

Cahill C, Holdridge S, Morinville A . Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci. 2006; 28(1):23-31. DOI: 10.1016/j.tips.2006.11.003. View

16.

Ross S, Peselow E . The neurobiology of addictive disorders. Clin Neuropharmacol. 2009; 32(5):269-76. DOI: 10.1097/wnf.0b013e3181a9163c. View

17.

Quock R, Burkey T, Varga E, Hosohata Y, Hosohata K, Cowell S . The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev. 1999; 51(3):503-32. View

18.

Abdelhamid E, Sultana M, Portoghese P, TAKEMORI A . Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther. 1991; 258(1):299-303. View

19.

Anand J, Purington L, Pogozheva I, Traynor J, Mosberg H . Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models. Chem Biol Drug Des. 2012; 80(5):763-70. PMC: 3465523. DOI: 10.1111/cbdd.12014. View

20.

Daniels D, Lenard N, Etienne C, Law P, Roerig S, Portoghese P . Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A. 2005; 102(52):19208-13. PMC: 1323165. DOI: 10.1073/pnas.0506627102. View